Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05977439
Other study ID # 00129566
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2024
Est. completion date October 1, 2028

Study information

Verified date April 2024
Source Medical University of South Carolina
Contact Jacob McTeague, PhD
Phone 843-792-8274
Email MCTEAGUE@MUSC.EDU
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this research study, the investigators are using examining how brain activity (electrical and blood flow) changes during tests of emotional processing and attention and memory in the magnetic resonance imaging (MRI) scanner. Investigators are also using non-invasive brain stimulation to probe different parts of the brain and measuring brain activity (electrical and blood flow). This study includes healthy participants and researchers hope this will help us develop improved brain-based treatments for emotional difficulties like depression.


Description:

Investigators hypothesize that targeted neuroplastic changes induced by individually-tailored rTMS will substantially reduce clinical symptoms underlying depression, anxiety and suicidality, and in general, revolutionize non-invasive treatments of mental health disorders. Investigators hypothesize that functional coupling in cognitive flexibility (CF) and emotion regulation (ER) networks is indexed by the phase of the brain's alpha oscillations. Using a novel integrated instrument that enables simultaneous functional magnetic resonance imaging (fMRI), electroencephalography (EEG) and transcranial magnetic stimulation (TMS), investigators propose to identify individualized stimulation parameters that reflect the strongest coupling of the CF/ER networks. The neuromechanistic model further posits that by applying repetitive TMS (rTMS) with these individualized parameters, one can induce entrainment in brain networks that drive neuroplastic changes in CF and ER. This initial Phase I Task 3 sub-study is a proof-of-principle study in healthy control participants.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date October 1, 2028
Est. primary completion date October 1, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Male or female - Age 18-65 - Endorse good health with no history of mental or physical illness or implanted metal - English as a primary language - Capacity to consent - Negative urine pregnancy test if female of childbearing potential - Willingness to adhere to the study schedule and assessments Exclusion Criteria: - Any current psychiatric diagnosis or current Clinical Global Impression ratings of psychiatric illness > 1 - Neurodevelopmental disorders, history of CNS disease, concussion, overnight hospitalization, or other neurologic sequela, tumors, seizures, meningitis, encephalitis, or abnormal CT or MRI of the brain - Any psychotropic medication is taken within 5 half-lives of procedure time - Any head trauma resulting in loss of consciousness - Visual impairment (except the use of glasses) - Inability to complete cognitive testing - Active participation or plan for enrollment in clinical trial affecting the psychosocial function - Repeated abuse or dependence upon drugs (excluding nicotine and caffeine) or taking medications including stimulants, modafinil, thyroid medication, or steroids - Implanted devices/ferrous metal of any kind - History of seizure or epilepsy, currently taking medications that lower seizure thresholds - Claustrophobia or other conditions that would prevent the MRI assessment. - Pregnancy (or suspected/possible pregnancy or plan to become pregnant in the short term). - Urine Pregnancy Test: If the subject is a woman of childbearing potential and /or a man capable of fathering a child before, during, and/or after participation precautions should be taken. Examples of acceptable methods of birth control for participants involved in the study include birth control pills, patches, IUDs, condoms, sponges, diaphragm with spermicide, or avoiding sexual activity that could cause the subject to become pregnant. - Inability to adhere to the treatment schedule.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
fMRI-EEG-TMS
Participants will undergo a magnetic resonance imaging (MRI) scan with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.

Locations

Country Name City State
United States Medical Univeristy of South Carolina Charleston South Carolina

Sponsors (5)

Lead Sponsor Collaborator
Medical University of South Carolina Columbia University, Defense Advanced Research Projects Agency, University of Oklahoma, University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in reaction time (RT) tasks - Incongruent Stimuli Tasks will be used to see differences between incongruent emotional stimuli. Day 1, Day 2, Day 3
Primary Change in reaction time (RT) tasks - Congruent Stimuli Tasks will be used to see differences between congruent emotional stimuli. Day 1, Day 2, Day 3
Primary Change in reaction time (RT) tasks and accuracy - Incongruent Stimuli Tasks will be used to see differences between incongruent emotional stimuli. Day 1, Day 2, Day 3
Primary Change in reaction time (RT) tasks and accuracy - Congruent Stimuli Tasks will be used to see differences between congruent emotional stimuli. Day 1, Day 2, Day 3
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1